We provide you with 20 years of free, institutional-grade data for IKT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of IKT. Explore the full financial landscape of IKT stock.
| Reported Date | CIK | Ticker | Type |
|---|
Inhibikase Therapeutics, Inc(NASDAQ:IKT) 
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease, and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a c-Abl protein kinase inhibitor for use in the treatment of P...
Share this website to your friends
The information provided in this report about IKT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.